General Inclusion Criteria:
* Body Mass Index (BMI) between 18.0 and 42.0 kg/m\^2, inclusive
* Generally stable health (except for hepatic impairment in hepatically impaired participants) as determined by the Investigator based on medical evaluation at Screening and Check-in, with no clinically significant findings that would interfere with study participation
* Female participants of non-childbearing potential who meet any of the following criteria: surgically sterile or postmenopausal
* Male participants are eligible if vasectomized or if they agree to the use of barrier contraception with other highly effective methods if sexually active with women of childbearing potential, during study treatment and for at least 7 days after the dose of study drug
Inclusion Criteria for Severe Hepatic Impairment Group:
* Severe hepatic dysfunction per National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria (serum total bilirubin \> 3 × upper limit of normal \[ULN\], any aspartate aminotransferase \[AST\])
* Clinically stable hepatic disease, in the opinion of the investigator, with no clinically significant worsening of hepatic function within 4 weeks prior to dosing
Inclusion Criteria for Normal Hepatic Function Group:
* Normal hepatic function, including total bilirubin ≤ ULN and AST ≤ ULN
* Absolute B-cell count of \> 150 cells/μL
General Exclusion Criteria:
* Any clinically significant disease or condition that, in the opinion of the Investigator, would interfere with study participation, safety, or evaluation of study results
* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator
* Evidence of any infections (bacterial, viral, fungal, parasitic) within 2-4 weeks prior to the first dose of study drug, as determined by the investigator (or designee)
* Positive urine drug screen or alcohol urine/breath test/blood results at screening or check-in
* History of alcoholism or drug/chemical abuse within the last 2 years
Exclusion Criteria for Severe Hepatic Impairment Group:
* Acute hepatic disease or rapidly deteriorating hepatic function
* History of liver transplantation
* Previously diagnosed hepatocellular carcinoma, or history of cholestatic liver disease or biliary sepsis within the past 2 years
Exclusion Criteria for Normal Hepatic Function Group:
* Any known or suspected hepatic disease
* Clinically significant abnormalities in liver function tests at Screening
* Require ongoing use of prescription or nonprescription medications, including herbal supplements (unless the medication is not expected to interfere with the pharmacokinetics, safety, or tolerability of the study drug)
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
